Phase III trial of AK111 for active ankylosing spondylitis completed with 510 patients

A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical study was conducted to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis. The study enrolled 510 patients. The research period was 61 weeks in total, consisting of three parts: a screening period (Part 1), a placebo control period (Part 2), and a long-term treatment follow-up period (Part 3). The intervention arms were AK111 and Placebo+AK111. The primary outcome measure was the response rate of ASAS20. The study was completed. The lead sponsor was Akeso. The study start date was November 22, 2023, and the primary completion date was February 19, 2025. The abstract does not report specific efficacy results, safety data, statistical significance, confidence intervals, hazard ratios, odds ratios, relative risks, p-values, or detailed patient demographics. The abstract also does not report the specific dosing regimen for AK111, the duration of the individual study periods, the criteria for active disease, prior treatment requirements, or any limitations of the study design.

If you have ankylosing spondylitis, you know the pain and stiffness it brings, especially in your spine. A large study involving 510 people with active forms of this condition tested whether a new drug called AK111 could help. The goal was to see if this treatment could safely help people feel and move better. The study was designed to be thorough and fair. It was randomized and double-blind, meaning neither the patients nor the doctors knew who was getting the real drug versus a placebo. This helps ensure the results are trustworthy. The main thing researchers were looking for was whether patients achieved what's called an ASAS20 response. This is a standard measure that means a person's symptoms—like pain, stiffness, and physical function—improved by at least 20%. The study lasted a total of 61 weeks and was divided into different parts, including an initial screening, a period where some received a placebo, and a long-term follow-up period to see how people did over time. The study is now complete, and the results will tell us if AK111 met its goal of helping a significant number of patients reach that meaningful improvement threshold. For anyone living with this condition, a new effective treatment could mean better daily management of pain and mobility.